World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
34025
World Ranking
9297
National Ranking
4797

Overview

Ashish M. Kamat is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical and surgical aspects of oncology, with a significant emphasis on urology and bladder cancer treatments.

The scientist's publication record spans 830 works within the field of Medicine, distributed across several specialized subfields including Surgery (536 publications), Oncology (88), Pulmonary and Respiratory Medicine (61), Molecular Biology (60), and Urology (60). The main topics addressed in their work include:

  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Urological Disorders and Treatments
  • Epigenetics and DNA Methylation
  • Cancer Immunotherapy and Biomarkers
  • Esophageal Cancer Research and Treatment
  • Renal cell carcinoma treatment

Recent notable papers authored or co-authored by Ashish M. Kamat include:

  • "Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study" (2021, The Lancet Oncology)
  • "Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial" (2020, The Lancet Oncology)
  • "Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors" (2023, European Urology)
  • "Current best practice for bladder cancer: a narrative review of diagnostics and treatments" (2022, The Lancet)
  • "Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma" (2020, Nature Medicine)

The venues most frequently publishing their work include:

  • The Journal of Urology (69 publications)
  • Journal of Clinical Oncology (52)
  • Urologic Oncology Seminars and Original Investigations (35)
  • European Urology (32)
  • European Urology Oncology (32)

Frequent collaborators in their research projects are:

  • Colin P. Dinney
  • Roger Li
  • Neema Navai
  • Kelly K. Bree
  • Patrick J. Hensley

Best Publications

  • Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration

    Vitaly Margulis;Shahrokh F. Shariat;Surena F. Matin;Ashish M. Kamat

  • Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

    Sam S. Chang;Bernard H. Bochner;Roger Chou;Robert Dreicer

  • Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

    Marcus George Kwesi Cumberbatch;Ibrahim Jubber;Peter C. Black;Francesco Esperto

  • CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

    Chrysoula I. Liakou;Ashish Kamat;Derek Ng Tang;Hong Chen

  • Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

    Bradley C. Carthon;Jedd D. Wolchok;Jianda Yuan;Ashish Kamat

  • Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

    David J. McConkey;Woonyoung Choi;Lauren Marquis;Frances Martin

  • Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

    Ashish M. Kamat;Richard J. Sylvester;Andreas Böhle;Joan Palou

  • Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.

    Arjun V Balar;Ashish M Kamat;Girish S Kulkarni;Edward M Uchio

  • Focus on bladder cancer

    Colin P.N. Dinney;David J. McConkey;Randall E. Millikan;Xifeng Wu

  • Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.

    Ashish M. Kamat;Colin P. N. Dinney;Jason R. Gee;H. Barton Grossman

  • A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

    David J McConkey;Woonyoung Choi;Yu Shen;I. Ling Lee

  • Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

    Ashish M. Kamat;Thomas W. Flaig;H. Barton Grossman;Badrinath Konety

  • ZKSCAN3 Is a Master Transcriptional Repressor of Autophagy

    Santosh Chauhan;Jinesh G. Goodwin;Swati Chauhan;Ganiraju Manyam

  • Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

    Marcus George Kwesi Cumberbatch;Beat Foerster;Beat Foerster;James W.F. Catto;Ashish M. Kamat

  • ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers

    Ashish M. Kamat;Paul K. Hegarty;Jason R. Gee;Peter E. Clark

  • Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

    Stephen A. Boorjian;Mehrdad Alemozaffar;Badrinath R. Konety;Neal D. Shore

  • An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer

    Girish S. Kulkarni;Oliver W. Hakenberg;Juergen E. Gschwend;George Thalmann

  • Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma.

    Surena F. Matin;Vitaly Margulis;Ashish Kamat;Christopher G. Wood

  • Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

    Hong Chen;Chrysoula I. Liakou;Ashish Kamat;Curtis Pettaway

  • Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.

    Jianjun Gao;Neema Navai;Omar Alhalabi;Arlene Siefker-Radtke

Frequent Co-Authors

Colin P. Dinney
Colin P. Dinney The University of Texas MD Anderson Cancer Center
H. Barton Grossman
H. Barton Grossman The University of Texas MD Anderson Cancer Center
Louis L. Pisters
Louis L. Pisters The University of Texas MD Anderson Cancer Center
Wassim Kassouf
Wassim Kassouf McGill University
Surena F. Matin
Surena F. Matin The University of Texas MD Anderson Cancer Center
Bogdan Czerniak
Bogdan Czerniak The University of Texas MD Anderson Cancer Center
Seth P. Lerner
Seth P. Lerner Baylor College of Medicine
Shahrokh F. Shariat
Shahrokh F. Shariat Medical University of Vienna
Xifeng Wu
Xifeng Wu Zhejiang University
Yair Lotan
Yair Lotan The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees is a smart way to expand your career opportunities in the healthcare field. Many students interested in medicine consider online nursing programs, which offer flexibility and can fast-track entry into clinical roles.

Affordable options are available for those looking to advance their qualifications, such as the cheapest dnp programs for nurses pursuing doctoral-level expertise. For registered nurses wanting to earn their Bachelor of Science in Nursing, cheap rn to bsn programs provide a practical pathway to career growth without excessive cost.

If you hold a non-nursing bachelor’s degree but wish to enter the nursing field, direct entry msn programs for non-nursing majors online offer a streamlined route to a master’s degree and new career options.

Those seeking accessible nursing programs can review whats the easiest nursing program to get into? to find schools that cater to diverse educational backgrounds. These alternatives can be an excellent starting point or complement to a medical education in the USA.

Best Scientists Citing Ashish M. Kamat

Trending Scientists

Recently Published Articles